drugset / Trial / NCT03460808

The Combination of Atorvastatin, Acetylcysteine and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

NCT03460808

Phase 1/2 Unknown 200 enrolled Peking University People's Hospital
NaSingle-groupOpen-labelTreatment

Summary

Single-arm, open-lable, multicentre study to compare the efficacy and safety of atorvastatin, acetylcysteine plus danazol with danazol monotherapy in patients with corticosteroidresistant/relapsed ITP.

Timeline

Start
2018-03-10
Primary completion
2020-01-01
Completion
2023-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 20 mg Oral
Subject Danazol Other / unclassified 200 mg Oral
Subject N-acetylcysteine Small molecule 400 mg Oral